AstraZeneca PLC (AZN)vsCareCloud, Inc. (CCLD)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
CCLD
CareCloud, Inc.
$2.35
-2.08%
HEALTHCARE · Cap: $99.86M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 48587% more annual revenue ($60.44B vs $124.14M). AZN leads profitability with a 17.2% profit margin vs 7.9%. CCLD appears more attractively valued with a PEG of 0.31. CCLD earns a higher WallStSmart Score of 66/100 (B-).
AZN
Buy64
out of 100
Grade: C+
CCLD
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+58.0%
Fair Value
$5.33
Current Price
$2.35
$2.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Growing faster than its price suggests
Earnings expanding 5739.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
7.9% margin — thin
Operating margin of 3.4%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : CCLD
The strongest argument for CCLD centers on PEG Ratio, EPS Growth, Debt/Equity. Revenue growth of 13.2% demonstrates continued momentum. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : CCLD
The primary concerns for CCLD are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while CCLD is a value play — different risk/reward profiles.
CCLD carries more volatility with a beta of 1.60 — expect wider price swings.
CCLD is growing revenue faster at 13.2% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
CCLD scores higher overall (66/100 vs 64/100) and 13.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CareCloud, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. The company is headquartered in Somerset, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?